# EDGAR Filing Document

**Accession Number:** 0001762303
**File Stem:** 0001193125-26-224022
**Filing Date:** 2026-5
**Character Count:** 21149
**Document Hash:** 859faef279f8e77068069bff408f26e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-224022.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001193125-26-224022

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260514

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVITA Medical, Inc.
- **CENTRAL INDEX KEY:** 0001762303
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 202578762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39059
- **FILM NUMBER:** 26978953

**BUSINESS ADDRESS:**
- **STREET 1:** 28159 AVENUE STANFORD
- **STREET 2:** SUITE 220
- **CITY:** VALENCIA
- **STATE:** CA
- **ZIP:** 91355
- **BUSINESS PHONE:** 661-568-1317

**MAIL ADDRESS:**
- **STREET 1:** 28159 AVENUE STANFORD
- **STREET 2:** SUITE 220
- **CITY:** VALENCIA
- **STATE:** CA
- **ZIP:** 91355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avita Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avita Medical, Ltd.
- **DATE OF NAME CHANGE:** 20181218

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 14, 2026<br>

------

AVITA Medical, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39059 | 85-1021707 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 28159 Avenue Stanford<br>Suite 220 |  |  |
| Valencia**,** California |  | 91355 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 661 367-9170<br>

N/A<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | RCEL | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On May 14, 2026, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.**  | **Description of Exhibit** |
| 99.1 | [<u>Press release, dated May 14, 2026, issued by AVITA Medical, Inc.</u>](rcel-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | AVITA Medical, Inc.  |
| Date: | May 14, 2026 | By:  | /s/ David O'Toole |
|  |  |  | David O'Toole<br>Chief Financial Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img262816717_0.gif](img262816717_0.gif)

**AVITA Medical Reports First Quarter 2026 Financial Results**

**VALENCIA, Calif., May 14, 2026** (GLOBE NEWSWIRE) — AVITA Medical<sup>®</sup>, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026.

**First Quarter 2026 Financial Highlights and Recent Business Updates**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx<sup>®</sup> and improved RECELL<sup>®</sup> utilization as reimbursement dynamics normalize

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Appointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a special committee of the Board of Directors, reflecting confidence in the Company's strategic direction and operational progress; Jan Stern Reed appointed as independent Chair of the Board

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Gross profit margin of 81.7%, reflecting impact of product mix and certain inventory adjustments

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Operating expenses decreased 11% year-over-year to $24.5 million, reflecting a lower and more disciplined cost base established in 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Net cash use of approximately $9.9 million in the quarter, reflecting one-time items and the timing of revenue and collections; cash use expected to decrease significantly in the second quarter

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Net loss of $10.6 million, or a loss of $0.35 per basic and diluted share, compared to $13.9 million, or a loss of $0.53 per basic and diluted share, in the first quarter of 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Entered into a 10-year BARDA agreement valued at up to $25.5 million to support U.S. burn emergency preparedness, providing recurring readiness revenue

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Announced positive interim Cohealyx I data demonstrating a ~20-day reduction in mean time to skin grafting readiness (13.6 vs. 33.2 days; p<0.001), supporting its potential to drive improved clinical outcomes and broader adoption

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Received regulatory clearance for RECELL GO<sup>®</sup> in Australia and New Zealand, supporting commercialization

Cary Vance, President and Chief Executive Officer of AVITA Medical, commented:

"Since November, we've stabilized the business, improved how we operate, and delivered a solid start to 2026. With sequential revenue growth and improving ordering patterns across the portfolio, we are focused on delivering sustained performance as we move through the year. At April's American Burn Association annual meeting, it was exciting to see how our products, RECELL, Cohealyx and PermeaDerm<sup>®</sup>, are delivering meaningful outcomes for clinicians and their patients. I am incredibly proud and excited to lead AVITA as we continue to build towards the future of wound care."

David O'Toole, Chief Financial Officer, commented:

"First quarter results reflect continued progress against the cost optimization initiatives implemented in 2025, with operating expenses down meaningfully year-over-year. We are also operating well within the framework of our recently refinanced credit facility, with terms aligned to our current revenue trajectory and providing increased flexibility as we execute.

As expected, net cash use was higher in the first quarter, driven by seasonal compensation and other one-time payments, and further elevated by the timing of revenue and collections. Cash receipts lag revenue, and with a greater proportion of product sales occurring later in the first quarter, the contribution from collections within the period was reduced, and our cash use for the first quarter was negatively impacted.

As we move into the second quarter, these timing dynamics have reversed. Seasonal and one-time items are completed, and collections from strong late-first quarter revenue and early-second quarter sales activity are driving higher cash receipts. Combined with ongoing cost discipline, this gives us confidence in a significant decrease in cash use in the second quarter."

------

**Financial Guidance**

AVITA Medical is reaffirming its full-year 2026 guidance, reflecting confidence in continued execution and improving commercial momentum:

Full year 2026 revenue expected in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.

**First Quarter Financial Results**

Total revenue was approximately $19.3 million in the three months ended March 31, 2026, representing an increase of $0.7 million, or 4%, compared to $18.5 million in the prior-year period. The increase was driven by contributions from Cohealyx, RECELL GO mini<sup>®</sup> in trauma and smaller wounds, and continued normalization in RECELL utilization following the resolution of prior reimbursement headwinds.

As of March 2026, all seven Medicare Administrative Contractors (MACs) have published payment rates for clinician use of RECELL, supporting broader and more consistent utilization.

Gross profit margin was 81.7%, compared to 84.7% in the prior-year period, reflecting product mix and inventory-related adjustments. RECELL demand remained solid during the quarter and the change in overall margin reflects the Company's deliberate expansion of its product portfolio, with Cohealyx and PermeaDerm. The Company shares the average sales price for Cohealyx at 50% and for PermeaDerm at 60%, which inevitably results in an overall decrease in gross margin percentage. The product mix is expected to continue to impact the overall gross margin percentage while increasing the gross profit and, given that expenses associated with this revenue do not increase significantly, operating profit on a quarterly basis. RECELL-only gross margin was 85.0% for the quarter.

Total operating expenses were approximately $24.5 million, compared to $27.5 million in the prior-year period, representing a decrease of $3.0 million, or 11%. The reduction reflects continued execution against cost optimization initiatives and sales force reduction implemented in 2025, which resulted in a $2.0 million decline in sales and marketing expenses driven by lower salaries, benefits, stock-based compensation, and commissions. General and administrative expenses decreased by $0.3 million, while research and development expenses decreased by $0.7 million, primarily due to lower personnel-related and program costs.

Net cash use for the quarter was approximately $9.9 million. The increase reflects the timing of annual compensation and other one-time items, as well as the timing of revenue and collections within the period. Cash receipts lag revenue, and with a greater proportion of sales activity occurring later in the first quarter, cash use was negatively impacted.

The Company ended the quarter with approximately $14.3 million in cash and marketable securities, compared to $18.2 million at the start of the quarter.

Net loss was $10.6 million, or a loss of $0.35 per basic and diluted share, compared to a net loss of $13.9 million, or a loss of $0.53 per basic and diluted share, in the same period in 2025.

**Webcast and Conference Call Information**

AVITA Medical will host a conference call on Thursday, May 14, 2026, at 1:30 p.m. Pacific Standard Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its first quarter 2026 financial results and recent business highlights. To listen to the conference call webcast, please register and join using the following link: https://edge.media-server.com/mmc/p/t54pdcd4. To participate in the live earnings conference call, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI27b7d18fc52c43599f75b727d38f8883. For those unable to participate in the live broadcast, a replay will be available on the Events page of the Company's investor relations website at: https://ir.avitamedical.com/events-and-presentations.

------

**About AVITA Medical, Inc.**

AVITA Medical<sup>®</sup> is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL<sup>®</sup>, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx<sup>®</sup>, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm<sup>®</sup>, a biosynthetic wound matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO<sup>®</sup> are CE-marked in Europe, have TGA certification in Australia, and Medsafe WAND listing in New Zealand; RECELL is PMDA-approved in Japan.

To learn more, visit www.avitamedical.com.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**<br>This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "approximately," "continue," "could," "expect," "future," "guidance," "may," "will," and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; anticipated market share growth and revenue generation; physician acceptance, endorsement, and use of our products (including the impact of government reimbursement payment rates on such use); failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this earnings release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

**Investor & Media Contact:**

Ben Atkins

Phone +1-805 341 1571

investor@avitamedical.com

media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.©2026 AVITA Medical. AVITA Medical<sup>®</sup>, Cohealyx<sup>®</sup>, RECELL<sup>®</sup>, RECELL GO<sup>®</sup>, and Spray-On Skin<sup>TM</sup> are trademarks of AVITA Medical. PermeaDerm<sup>®</sup> is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.

------

**AVITA MEDICAL, INC.**

**Consolidated Balance Sheets**

**(In thousands, except share and per share data)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **March 31, 2026** | **December 31, 2025** |
| ASSETS |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $8309 | $10243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 5952 | 7942 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 9885 | 9086 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaids and other current assets | 1384 | 1293 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 6117 | 6926 |
| Total current assets | 31647 | 35490 |
| &nbsp;&nbsp;&nbsp;&nbsp;Plant and equipment, net | 8211 | 8630 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 2666 | 2899 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate-owned life insurance ("COLI") asset | 3044 | 3116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 5442 | 5645 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 534 | 612 |
| Total assets | $51544 | $56392 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $7220 | $8959 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued wages and fringe benefits | 7870 | 7813 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loan facility | 46139 | 42984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current non-qualified deferred compensation ("NQDC") liability | 276 | 276 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent liability | 3000 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 2166 | 2645 |
| Total current liabilities | 66671 | 62677 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-qualified deferred compensation liability | 3584 | 3697 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 281 | 290 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, long-term | 1981 | 2135 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent liability, long-term | - | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrant liabilities | 2193 | 1243 |
| Total liabilities | 74710 | 73042 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commitments and contingencies |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stockholders' equity (deficit): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 3 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Company common stock held by the non-qualified deferred compensation plan | (635) | (1293) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 395830 | 394408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 648 | (1367) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (419012) | (408401) |
| Total stockholders' equity (deficit) | (23166) | (16650) |
| Total liabilities and stockholders' equity (deficit) | $51544 | $56392 |

---

------

**AVITA MEDICAL, INC.**

**Consolidated Statements of Operations**

**(In thousands, except share and per share data)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three-Months Ended** | **Three-Months Ended** |
|  | **March 31, 2026** | **March 31, 2025** |
| &nbsp;&nbsp;Sales revenue | $19064 | $18325 |
| &nbsp;&nbsp;Lease revenue | 187 | 189 |
| Total revenues | 19251 | 18514 |
| Cost of sales | (3523) | (2833) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 15728 | 15681 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | (12841) | (14834) |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | (6061) | (6390) |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | (5629) | (6284) |
| Total operating expenses | (24531) | (27508) |
| Operating loss | (8803) | (11827) |
| Interest expense | (1424) | (1233) |
| Other expense, net | (395) | (791) |
| Loss before income taxes | (10622) | (13851) |
| Income tax benefit (expense) | 11 | (8) |
| Net loss | $(10611) | $(13859) |
| Net loss per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(0.35) | $(0.53) |
| Weighted-average common shares: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 30540872 | 26253565 |

---

------